Study ID: C38072-AS-40105
Study Title
- An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation
Teva Identifier
- C38072-AS-40105
ClinicalTrials.gov Identifier
- NCT02937168
Study Status
- Terminated
Trial Condition(s)
- Asthma
Interventions
- Drug: Reslizumab | Drug: Fludeoxyglucose F 18 (FDG) | Drug: Placebo
Study Description
- Please refer to ClinicalTrials.gov for a description of the trial

Key Participation Requirements
Gender
- Female, Male
Age Range
- 18 Years to 50 Years
Trial Duration
- May 8, 2017 - May 24, 2017
Phase
- Phase 4
Study Type
Interventional